この記事を読む

緻密な高齢者評価・ケアでもがん患者のQOLはあまり改善せず

Impact of Geriatric Assessment and Management on Quality of Life, Unplanned Hospitalizations, Toxicity, and Survival for…

この記事を読む

毒性中止したICIの再投与は適切か

Immune Checkpoint Inhibitor Rechallenge Safety and Efficacy in Stage IV Non-Small Cell Lung Cancer Patients After Immune…

この記事を読む

非喫煙者における肺癌、トレンドは変わってきている?

Lung cancer in never smokers: Distinct population-based patterns by age, sex, and race/ethnicity. Pinheiro PS et al.Lung…

この記事を読む

ALTA-2:アレクチニブ後のブリグチニブ

Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lun…

この記事を読む

ICI化学療法終了後のラムシルマブ+アテゾリズマブ

Ramucirumab plus atezolizumab in patients with stage IV non-small cell lung cancer previously treated with immune checkp…

この記事を読む

肺癌患者へのブースター接種後のオミクロン株に対する抗体の推移

Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivi…

この記事を読む

肺癌治療の進歩にもかかわらず、まだ気管支漏には対処が難しい

Bronchorrhea, a Rare and Debilitating Symptom of Lung Cancer: Case Report and Review of the Treatment. Bhagat M et al.JT…

この記事を読む

PETによる原発巣と転移巣の効果判定の不一致

18F-FDG PET/CT for assessing heterogeneous metabolic response between primary tumor and metastases and prognosis in non-…

この記事を読む

ペムブロリズマブ3週から6週間隔への変更でirAEが増える可能性

Safety Implications of Switching Pembrolizumab Dosage From 200 mg Every 3 Weeks to 400 mg Every 6 Weeks in Patients With…

この記事を読む

小細胞肺癌に対する免疫療法の実地データ

Real-world evidence for immunotherapy in the first line setting in small cell lung cancer Shira Sagie et al.lung Cancer …